Latest Health News

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.

Finbar Group has reinstated regular dividends with a fully franked 2 cent final payout for FY25, supported by a robust $36 million cash reserve and a strong development pipeline exceeding $1 billion in value.

Pengana Capital Group has reported a solid increase in funds under management, reaching $3.64 billion as of June 30, 2025, alongside modest net performance fees and upcoming distributions.

BPH Global Ltd (ASX, BP8) has initiated strategic discussions with Indonesia’s National Economic Council to deploy its innovative seaweed-based bioremediation solutions targeting pollution from nickel and coal mining operations.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Ava Risk Group has suspended its dividend policy to reinvest capital into its growth strategy, signaling a shift in priorities for shareholders. The board will reassess this stance annually.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.

Great Dirt Resources has secured a significant exploration licence in the Pilbara lithium province and bolstered its finances with a $335,000 R&D tax rebate, setting the stage for accelerated exploration activities.

Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.

Kingsgate Consolidated’s Chatree Gold Mine delivered a robust quarter with gold production exceeding 20,000 ounces, aligning with its revised FY25 guidance and boosting cash reserves.